Supplements
quercetin treats COVID-19
In plain terms: Does quercetin help treat COVID-19?
Part of: 🧪 quercetin
Unproven, and the evidence base has a specific weakness: not one blinded trial exists. The positive trials are all open-label, mostly small, and heavily concentrated in one group's branded product or in combination pills that cannot isolate quercetin.
📅 Last reviewed: 2026-07-26 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Not one double-blind placebo-controlled trial exists in this literature. Every primary trial is OPEN-LABEL, most are small (n=42-152) and single-centre, and a large share of the positive signal traces to one Italian group's proprietary phytosome product or to Pakistani trials stacking quercetin with curcumin and vitamin D3 (so quercetin's own contribution is not isolable).
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Di Pierro F et al 2022 · study_type: RCT | RCT | mixed | low | Open-label RCT, Lahore Pakistan, n=100 early-stage mild-to-moderate outpatients: 500mg Quercetin Phytosome® added to standard care vs standard care alone; faster viral clearance (34 vs 12 PCR-negative at 1wk, p=0.0004), faster symptom resol TEMPERED: open-label, same commercial phytosome product. |
| Shohan M et al 2022 · study_type: RCT | RCT | mixed | low | Open-label RCT, n=60 severe hospitalized COVID-19 patients: 1000mg/day quercetin added to remdesivir/favipiravir for 7 days vs antivirals alone; quercetin group had lower ALP/CRP/LDH and somewhat earlier discharge, but mortality, ICU-admiss TEMPERED: open-label; hard endpoints (mortality, ICU) were non-significant. |
| Di Pierro F et al 2021 · study_type: RCT | RCT | mixed | low | Prospective randomized open-label trial, Italy, n=152 COVID-19 outpatients: 1000mg/day Quercetin Phytosome® (QP) for 30 days as adjuvant to standard care; abstract reports reduced frequency/length of hospitalization, need for oxygen therapy TEMPERED: open-label, and from the group/product that dominates this literature — direction cannot be separated from unblinding and network concentration. |
| Piva M et al 2026 · study_type: observational | observational | supports | low | Narrative review of 5 flavonoids (2020-2025 literature survey) lists as a 'clinical highlight' that quercetin phytosome administration 'accelerated SARS-CoV-2 clearance,' alongside a separate quercetin-NAFLD liver-fat finding — but gives no |
| Onal H et al 2021 · preprint | RCT | mixed | low | Single-centre, open-label RCT (no blinding, no placebo — QCB vs routine care) of QCB (quercetin + vitamin C + bromelain, a combination, not isolated quercetin) in 447 COVID-19 inpatients with comorbidities: QCB improved CRP/procalcitonin/fe |
| Ziaei S et al 2023 · study_type: meta-analysis | meta-analysis | supports | low | SR/MA of 5 RCTs, n=544 COVID-19 patients (search to Aug 2023): quercetin reduced LDH (SMD -0.42, 95% CI -0.82 to -0.02) and cut hospital admission 70% (RR 0.30), ICU admission 73% (RR 0.27), and mortality 82% (RR 0.18), with no significant |
| Gérain J et al 2023 · study_type: RCT | RCT | mixed | low | Open-label RCT, n=49 hospitalized COVID-19 adults (Europe, NCT04844658): Nasafytol® (curcumin+quercetin+vitamin D3, NOT quercetin alone) vs a vitamin-D comparator (Fultium®) as add-on to standard care; more discharges by day 7 (19 vs 10), f TEMPERED: open-label combination product — quercetin's own contribution is not isolable. |
| Di Pierro F et al 2021 · study_type: RCT | RCT | mixed | low | Second pilot open-label RCT, Italy, n=42 COVID-19 outpatients: Quercetin Phytosome® (QP) add-on to SOC vs SOC; faster viral clearance (16/21 negative at 1wk vs 2/21 SOC) and larger drops in LDH (-35.5%), ferritin (-40%), CRP (-54.8%), D-dim TEMPERED: open-label pilot from the same group/product as the trial above. |
| Cheema HA et al 2023 · study_type: meta-analysis | meta-analysis | mixed | low | MA of 6 RCTs (search to Oct 2022): quercetin reduced ICU admission (OR 0.31, 95% CI 0.10-0.99) and hospitalisation (OR 0.25, 95% CI 0.10-0.62) but did NOT reduce all-cause mortality or improve the 'no-recovery' rate; authors flag benefit wa TEMPERED: pools the same small open-label non-independent trial set; inherits its bias. |
| Ujjan ID et al 2022 · study_type: RCT | RCT | mixed | low | Exploratory open-label RCT, Jamshoro Pakistan, n=50 early-stage COVID-19 outpatients: curcumin+quercetin (168mg+260mg BID, 14 days) add-on vs standard-of-care alone; viral RT-PCR negativity 72% vs 24% (p=0.0002), but symptom resolution diff TEMPERED: open-label combination (curcumin+quercetin+vit D3) — quercetin not isolated. |
| Khan A et al 2022 · study_type: RCT | RCT | mixed | low | Pilot open-label RCT, Lahore Pakistan (Mayo Hospital), n=50 mild-to-moderate COVID-19 outpatients: curcumin+quercetin+vitamin D3 (CQC, 14 days) add-on to SOC vs SOC; faster RT-PCR negativization (60% vs 20%, p=0.009) and greater CRP drop (p TEMPERED: open-label combination (curcumin+quercetin) — quercetin not isolated. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.